To confirm our funding, we added critical clinical characteristics such as diagnosed age, GS, tumor T stage and N stage, the above three m6A methylation regulators (IGF2BP3, HNRNPA2B1, and METTL14) were still remarkably related with prognosis of prostate cancer. This evidence concerns the gene METTL14 and neoplasm.